2013 NEI Psychopharmacology Congress

2013 NEI Psychopharmacology Congress | NEI 2013

The 2013 Neuroscience Education Institute Psychopharmacology Congress will feature “the finest in psychopharmacology,” brought to you by “a group of exceptional clinicians and elite speakers who will inspire and inform you of the latest treatment strategies.” Attendees will learn about the latest drugs and new ways to use established drugs.

Conference Coverages

Executive Function Disorder and ADHD
Executive Function Disorder and ADHD
Executive function disorder and ADHD share several overlapping symptoms, and the presence of executive function impairment is often associated with a diagnosis of ADHD. Clinicians should be aware of the testing modalities that can help accurately identify executive function disorder, and also be aware of the limitations of current medications when it comes to mitigating symptoms.
Long-Term Treatment of Schizophrenia with Depot Medication
Depot antipsychotic medications for patients with schizophrenia are often associated with improved treatment adherence.
Effective Tools for Dealing with Aggressive and Violent Psychiatric Patients in the Inpatient Setting
Creating a safer environment for clinicians and patients starts with better formalized reporting of aggressive and violent behavior, and should also include more rigorous screening and assessment for risk markers of violent behavior.
Schizophrenia: Crafting a New Approach to Treatment Tolerability
Genotyping and access to more genetic information about patients may allow clinicians to minimize side effects associated with treatment for schizophrenia by choosing antipsychotic agents based on their unique molecular binding profiles and using the lowest effective doses.
Integrating Non-pharmacologic Modalities into Major Depressive Disorder Treatment
Evidence shows that interventional approaches such as transcranial magnetic stimulation, electroconvulsive therapy, deep brain stimulation, and bright light therapy, coupled with mindfulness-based cognitive therapy, can be an effective part of treatment for major depressive disorder.
The Changing Face of Bipolar Care: Initial Results of the MedRisk Study
Study looks at an integrated care model for treating bipolar depression that incorporates a multidisciplinary care team, individualized lifestyle interventions, focused patient education, weight loss and nutrition counseling, and efforts to promote treatment adherence.
Genotyping and the Future of Psychiatric Treatment
Although we have made great advances in understanding the genetic components of psychiatric illness, caution is essential when applying information from genetic testing to the selection of treatment in clinician practice.
Expert Tips for Assessing, Diagnosing, and Managing Bipolar Depression
Presentation at the 2013 NEI Psychopharmacology Congress noted potential "red flag" symptoms and events that indicate increased risk of bipolar depression, and discussed several medication options for effectively managing this mental health disorder.
Major Disasters and the Mental Health Community
Planning and preparation prior to a disaster, developing networks of contacts with other medical personnel and facilities, avoiding overburdening medical staff and personnel in the aftermath of a disaster, and effectively treating PTSD and other mental health disorders are the keys to disaster preparedness.

Most Popular


$vacMongoViewPlus$ $vAR$